Edwards Lifesciences Corporation (EW) Cash Flow Statement

The 2026Q1 ratio of 0.12 and the 2025Q4 ratio of 4.94 suggest that quarterly working capital movements, rather than underlying earnings power, are driving much of the period-to-period cash result. Sustained conversion above 1.0 in most quarters is a positive quality signal, but the magnitude of the swings warrants investigation before treating any single quarter as representative. Investors should monitor whether the trailing-twelve-month ratio converges toward a stable level.

The 2026Q2 margin of 33.6% and 2026Q3 margin of 29.5% sit above the 15.7% to 23.6% range seen across much of 2024 and 2025, which suggests improved underlying cash generation. However, the 2026Q1 negative figure was driven by a $501.5M working capital outflow, indicating the recent strength may depend partly on reversing that build. Sustainability likely hinges on whether working capital stays contained over the next several quarters.

Capital intensity this low is consistent with a medtech model where manufacturing spend is limited relative to revenue, supporting high conversion of operating cash into free cash flow. The 2025Q4 spike to 6.2% is an outlier worth monitoring, as it may reflect a timing-driven facility or equipment investment rather than a structural shift. Depreciation of roughly $35M to $50M per quarter sits below capex in most periods, suggesting the company is modestly investing ahead of asset consumption.

These swings are consistent with the consignment inventory model noted in the business profile, where hospital stocking patterns and implant-triggered revenue recognition can shift receivables and inventory materially within a quarter. The 2024Q3 inflow coincides with an elevated net income print, which warrants scrutiny of whether one-time items contributed. Investors should track inventory at customer locations and receivable days to distinguish genuine collection improvement from timing effects.

The absence of dividends alongside sizable buybacks suggests management prioritizes share repurchases and selective acquisitions over income distribution, consistent with a growth-oriented capital allocation posture. Large buybacks in periods of heavy working capital outflow, such as 2026Q1 with $521.8M repurchased, may indicate capital returns are not always funded from the quarter's free cash flow. Investors should assess whether repurchases are sustainably covered by trailing free cash flow.